Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration

Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target sites...

Descripción completa

Detalles Bibliográficos
Autores principales: Sleiman, Sama F., Berlin, Jill, Basso, Manuela, S.Karuppagounder, Saravanan, Rohr, Jürgen, Ratan, Rajiv R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349345/
https://www.ncbi.nlm.nih.gov/pubmed/22582024
http://dx.doi.org/10.3390/ph4081183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349345/
https://www.ncbi.nlm.nih.gov/pubmed/22582024
http://dx.doi.org/10.3390/ph4081183

Ejemplares similares